-
公开(公告)号:US20100099082A1
公开(公告)日:2010-04-22
申请号:US12303075
申请日:2007-06-01
申请人: Thomas Lion , Peter Bader , Helene Cave , Mark Lawler , Andrea Biondi , Anna Serra , Jacques J. M. Van Dongen , Marcel G.J. Tilanus , Marcos Gonzalez Diaz , Gisela Barbany , Eddy Roosnek , Colin G. Steward
发明人: Thomas Lion , Peter Bader , Helene Cave , Mark Lawler , Andrea Biondi , Anna Serra , Jacques J. M. Van Dongen , Marcel G.J. Tilanus , Marcos Gonzalez Diaz , Gisela Barbany , Eddy Roosnek , Colin G. Steward
CPC分类号: C12Q1/6858 , C12Q1/6881 , C12Q2600/156 , C12Q2600/16
摘要: Method for simultaneously determining alleles present in a set of loci from at least one nucleic acid sample comprising the steps: a) providing said at least one sample, b) subjecting said sample to a nucleic acid amplification reaction using a primer pair simultaneously primer pairs specific and optimized for each of the loci of a set of at least three loci selected from the group consisting of D2S1360, D7S1517, D8S1132, D9S1118, D10S2325, D11S554, D12S1064, D12S391, D17S1290, D19S253, MYCLl, P450CYP19 and SE-33, and c) evaluating the length and optionally the relative quantity of amplification products obtained from step b) or from the analysis of one or two of the above loci to determine and/or optionally quantify the alleles present at each of the loci analyzed in the set within said sample.
摘要翻译: 同时测定来自至少一个核酸样品的一组基因座中存在的等位基因的方法,包括以下步骤:a)提供所述至少一个样品,b)使用引物对同时使用引物对进行核酸扩增反应,引物对特异性 并且针对从D2S1360,D7S1517,D8S1132,D9S1118,D10S2325,D11S554,D12S1064,D12S391,D17S1290,D19S253,MYCL1,P450CYP19和SE-33组成的组中选择的一组至少三个基因座的每个位点进行优化,以及 c)评估从步骤b)获得的扩增产物的长度和任选的相对量,或从上述一个或两个上述基因座的分析中确定和/或可选地定量存在于组中分析的每个基因座处的等位基因 说样品。
-
公开(公告)号:US20080076787A1
公开(公告)日:2008-03-27
申请号:US11882892
申请日:2007-08-06
申请人: Antonio Paredes , Javier Orpi , Elies Grau , Anna Serra , Kevin Meyer , Keith Lorimer
发明人: Antonio Paredes , Javier Orpi , Elies Grau , Anna Serra , Kevin Meyer , Keith Lorimer
IPC分类号: A61K31/517 , A61P31/00 , C07D401/02
CPC分类号: C07D403/06
摘要: Novel crystalline forms of (1R,2R)-7-chloro-3-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]quinazolin-4(3H)-one, pharmaceutical compositions containing these crystalline forms, methods of using these crystalline forms for treating and/or preventing various microbial and/or fungal infections or disorders, and processes for obtaining these crystalline forms. In particular, the present subject matter relates to the specific crystalline Forms I, II, III, IV, V, and VI of (1R,2R)-7-chloro-3-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]quinazolin-4(3H)-one.
摘要翻译: (1R,2R)-7-氯-3- [2-(2,4-二氟苯基)-2-羟基-1-甲基-3-(1H-1,2,4-三唑-1-基) 丙基]喹唑啉-4(3H) - 酮,含有这些结晶形式的药物组合物,使用这些结晶形式用于治疗和/或预防各种微生物和/或真菌感染或病症的方法,以及获得这些结晶形式的方法。 特别地,本主题涉及(1R,2R)-7-氯-3- [2-(2,4-二氟苯基)-2(2R,2R) (1H-1,2,4-三唑-1-基)丙基]喹唑啉-4(3H) - 酮。
-